Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05081609
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:21.880047+00:00
Published At
2026-02-24T00:00:00+00:00
Record Updated At
2026-02-24
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Solid Tumor", "Locally Advanced Solid Tumor", "Metastatic Solid Tumor", "Platinum-resistant Ovarian Cancer", "Post Anti-PD-1 Melanoma", "2L+ Cervical Cancer", "Neoadjuvant Melanoma", "Neoadjuvant Non-Small Cell Lung Cancer", "Post Anti-PD-(L)1 Non-Small Cell Lung Cancer", "Post Anti-PD-(L)1 Small Cell Lung Cancer", "Third Line or Later (3L+) HER2+ Breast Cancer", "Second or Third Line (2L/3L) Cervical Cancer", "Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-24"
protocolSection.identificationModule.nctId
"NCT05081609"
protocolSection.identificationModule.officialTitle
"IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Advanced Solid Tumor (protocolSection.conditionsModule.conditions)
  • Locally Advanced Solid Tumor (protocolSection.conditionsModule.conditions)
  • Metastatic Solid Tumor (protocolSection.conditionsModule.conditions)
  • Platinum-resistant Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Post Anti-PD-1 Melanoma (protocolSection.conditionsModule.conditions)
  • 2L+ Cervical Cancer (protocolSection.conditionsModule.conditions)
  • Neoadjuvant Melanoma (protocolSection.conditionsModule.conditions)
  • Neoadjuvant Non-Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Post Anti-PD-(L)1 Non-Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Post Anti-PD-(L)1 Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Third Line or Later (3L+) HER2+ Breast Cancer (protocolSection.conditionsModule.conditions)
  • Second or Third Line (2L/3L) Cervical Cancer (protocolSection.conditionsModule.conditions)
  • Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.